ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urethral Neoplasms
Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Urethral Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Carboplatin Astellas Pharma Global Development, Inc. | Phase 1/2 | B |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Astellas Pharma Global Development, Inc. | Phase 1/2 | CCC |
Pembrolizumab Astellas Pharma Global Development, Inc. | Phase 1/2 | CCC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →